EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
Gong H, et al. Among authors: zhang z, zhang h.
BMC Cancer. 2020 Dec 4;20(1):1189. doi: 10.1186/s12885-020-07667-7.
BMC Cancer. 2020.
PMID: 33276757
Free PMC article.